论文部分内容阅读
目的 探讨p16、死亡相关蛋白激酶 (death associatedproteinkinase ,DAP)基因的异常甲基化作为非小细胞肺癌 (NSCLC)患者诊断的基因标志物的可行性。方法 采用甲基化特异性PCR(MSP)法检测 3 0例NSCLC患者肿瘤组织及对应血清中p16、DAP基因的异常甲基化。结果 NCSLC肿瘤组织中 60 .0 % (18/3 0 )检测出至少一个基因启动子呈甲基化改变 ,在 18例肿瘤组织检测到异常甲基化的患者中 ,5 0 .0 %的患者 (9/18)在血清中检测到相应的改变 ,所有的癌旁组织、健康对照组的血清中及正常肺组织均未检测到p16、DAP的甲基化。结论 检测NCSLC患者血清中p16、DAP基因异常甲基化有可能成为肺癌诊断的分子标志物
Objective To investigate the possibility of aberrant methylation of p16 and death associated protein kinase (DAP) gene as a diagnostic biomarker for patients with non-small cell lung cancer (NSCLC). Methods Methylation-specific PCR (MSP) was used to detect abnormal methylation of p16 and DAP in tumor tissue and corresponding serum in 30 NSCLC patients. Results 60% (18/3 0) of at least one gene promoter in NCSLC tumor tissues showed methylation changes. Among the 18 patients with abnormal methylation detected in tumor tissues, 50.0% of patients (9/18) were detected in serum corresponding changes, all paracancerous tissue, healthy control group serum and normal lung tissue were not detected p16, DAP methylation. Conclusion Detection of abnormal methylation of p16 and DAP in serum of NCSLC patients may become a molecular marker for the diagnosis of lung cancer